Cell line · CVCL_0333
Papers33
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA double-strand breaks to promote nonhomologous end-joining. | Nucleic Acids Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes. | Pharmaceuticals (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Neotelomeres and telomere-spanning chromosomal arm fusions in cancer genomes revealed by long-read sequencing. | Cell Genom | 2024 | Its Methods give the RRID and name the line | PubMed | |
| YAP/TEAD-induced PRIM1 contributes to the progression and poor prognosis of gastric carcinoma. | Transl Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| E3 ligase MG53 suppresses tumor growth by degrading cyclin D1. | Signal Transduct Target Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. | Cell Mol Life Sci | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. | Clin Transl Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer. | Int J Mol Sci | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model. | BMC Cancer | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0333/papers